AVEO Pharmaceuticals, Inc. (AVEO) Receives $1.96 Average Target Price from Analysts

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) has been assigned an average recommendation of “Hold” from the nine analysts that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and four have given a buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $1.96.

A number of equities analysts recently weighed in on the stock. HC Wainwright downgraded shares of AVEO Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $1.00 target price on the stock. in a report on Friday, February 1st. ValuEngine downgraded shares of AVEO Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, January 31st. National Securities assumed coverage on shares of AVEO Pharmaceuticals in a report on Thursday, March 28th. They set a “sell” rating on the stock. BidaskClub upgraded shares of AVEO Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, January 15th. Finally, Robert W. Baird assumed coverage on shares of AVEO Pharmaceuticals in a report on Thursday, January 3rd. They set an “outperform” rating and a $3.00 target price on the stock.

In other news, major shareholder Equity Opportunities Fu Growth bought 4,347,827 shares of the stock in a transaction that occurred on Monday, April 8th. The shares were acquired at an average cost of $1.14 per share, for a total transaction of $4,956,522.78. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.40% of the stock is currently owned by insiders.

A number of hedge funds have recently added to or reduced their stakes in AVEO. NEA Management Company LLC boosted its position in AVEO Pharmaceuticals by 11.8% during the fourth quarter. NEA Management Company LLC now owns 20,896,038 shares of the biopharmaceutical company’s stock worth $33,434,000 after purchasing an additional 2,198,000 shares during the period. Geode Capital Management LLC boosted its position in AVEO Pharmaceuticals by 36.3% during the fourth quarter. Geode Capital Management LLC now owns 1,394,576 shares of the biopharmaceutical company’s stock worth $2,231,000 after purchasing an additional 371,327 shares during the period. D. E. Shaw & Co. Inc. bought a new position in AVEO Pharmaceuticals during the fourth quarter worth $455,000. BlackRock Inc. boosted its position in AVEO Pharmaceuticals by 3.3% during the fourth quarter. BlackRock Inc. now owns 7,357,716 shares of the biopharmaceutical company’s stock worth $11,773,000 after purchasing an additional 236,822 shares during the period. Finally, New York State Common Retirement Fund boosted its position in AVEO Pharmaceuticals by 261.3% during the fourth quarter. New York State Common Retirement Fund now owns 248,600 shares of the biopharmaceutical company’s stock worth $398,000 after purchasing an additional 179,800 shares during the period. 35.72% of the stock is owned by hedge funds and other institutional investors.

Shares of AVEO opened at $1.00 on Tuesday. The firm has a market cap of $140.39 million, a P/E ratio of -5.24 and a beta of 1.19. AVEO Pharmaceuticals has a 1-year low of $0.49 and a 1-year high of $3.59.

About AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).

See Also: Is the Dow Jones Industrial Average (DJIA) still relevant?

Analyst Recommendations for AVEO Pharmaceuticals (NASDAQ:AVEO)

Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.